POMALYST® (pomalidomide), in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
What you need to know about the POMALYST REMS® program
Your doctor will enroll you in the POMALYST REMS® program so that you can receive your medication. Use the materials below to learn more about the POMALYST REMS® program, and what you need to do.
You can take your mandatory confidential patient survey at CelgeneRiskManagement.com by clicking the button below or by using the Celgene REMS mobile app.
For additional information about the POMALYST REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
POMALYST® and POMALYST REMS® are registered trademarks of Celgene Corporation.
© 2016 year of origin. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.